🚀 VC round data is live in beta, check it out!
EKF Diagnostics Valuation Multiples
Discover revenue and EBITDA valuation multiples for EKF Diagnostics and similar public comparables like Nyxoah, Guerbet, AVITA Medical, Biodesix and more.
EKF Diagnostics Overview
About EKF Diagnostics
EKF Diagnostics Holdings PLC is engaged in development, manufacture and supply of products and services into the in-vitro diagnostic (IVD) market place. The Group has presence in the UK, USA, Germany, and Russia, and sells throughout the world including Europe, the Middle East, the Americas, Asia, and Africa. It derive their revenue from the manufacture and sale of medical diagnostic equipment and reagents. Other services include the servicing and distribution of third party company products under separate distribution agreements.
Founded
2002
HQ
Employees
303
Website
Financials (LTM)
EV
$127M
EKF Diagnostics Financials
EKF Diagnostics reported last 12-month revenue of $70M and EBITDA of $17M.
In the same LTM period, EKF Diagnostics generated $36M in gross profit, $17M in EBITDA, and $5M in net income.
Revenue (LTM)
EKF Diagnostics P&L
In the most recent fiscal year, EKF Diagnostics reported revenue of $68M and EBITDA of $15M.
EKF Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $70M | XXX | $68M | XXX | XXX | XXX |
| Gross Profit | $36M | XXX | $33M | XXX | XXX | XXX |
| Gross Margin | 51% | XXX | 48% | XXX | XXX | XXX |
| EBITDA | $17M | XXX | $15M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 22% | XXX | XXX | XXX |
| EBIT Margin | 16% | XXX | 13% | XXX | XXX | XXX |
| Net Profit | $5M | XXX | $8M | XXX | XXX | XXX |
| Net Margin | 6% | XXX | 12% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
EKF Diagnostics Stock Performance
EKF Diagnostics has current market cap of $143M, and enterprise value of $127M.
Market Cap Evolution
EKF Diagnostics' stock price is $0.33.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $127M | $143M | 0.0% | XXX | XXX | XXX | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialEKF Diagnostics Valuation Multiples
EKF Diagnostics trades at 1.8x EV/Revenue multiple, and 7.4x EV/EBITDA.
EV / Revenue (LTM)
EKF Diagnostics Financial Valuation Multiples
As of April 20, 2026, EKF Diagnostics has market cap of $143M and EV of $127M.
Equity research analysts estimate EKF Diagnostics' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
EKF Diagnostics has a P/E ratio of 31.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $143M | XXX | $143M | XXX | XXX | XXX |
| EV (current) | $127M | XXX | $127M | XXX | XXX | XXX |
| EV/Revenue | 1.8x | XXX | 1.9x | XXX | XXX | XXX |
| EV/EBITDA | 7.4x | XXX | 8.4x | XXX | XXX | XXX |
| EV/EBIT | 11.0x | XXX | 14.9x | XXX | XXX | XXX |
| EV/Gross Profit | 3.5x | XXX | 3.9x | XXX | XXX | XXX |
| P/E | 31.6x | XXX | 17.0x | XXX | XXX | XXX |
| EV/FCF | 15.0x | XXX | 8.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified EKF Diagnostics Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
EKF Diagnostics Margins & Growth Rates
EKF Diagnostics' revenue in the last 12 month grew by 7%.
EKF Diagnostics' revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
EKF Diagnostics' rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
EKF Diagnostics' rule of X is 45% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
EKF Diagnostics Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 1% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 22% | XXX | XXX | XXX |
| EBITDA Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 45% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 27% | XXX | 36% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 35% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
EKF Diagnostics Public Comps
See public comps and valuation multiples for other Medical Devices and Medical Imaging & Diagnostics comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| EKF Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Nyxoah | XXX | XXX | XXX | XXX | XXX | XXX |
| Guerbet | XXX | XXX | XXX | XXX | XXX | XXX |
| AVITA Medical | XXX | XXX | XXX | XXX | XXX | XXX |
| Biodesix | XXX | XXX | XXX | XXX | XXX | XXX |
| Paxman | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
EKF Diagnostics M&A Activity
EKF Diagnostics acquired XXX companies to date.
Last acquisition by EKF Diagnostics was on XXXXXXXX, XXXXX. EKF Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by EKF Diagnostics
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialEKF Diagnostics Investment Activity
EKF Diagnostics invested in XXX companies to date.
EKF Diagnostics made its latest investment on XXXXXXXX, XXXXX. EKF Diagnostics invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by EKF Diagnostics
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout EKF Diagnostics
| When was EKF Diagnostics founded? | EKF Diagnostics was founded in 2002. |
| Where is EKF Diagnostics headquartered? | EKF Diagnostics is headquartered in United Kingdom. |
| How many employees does EKF Diagnostics have? | As of today, EKF Diagnostics has over 303 employees. |
| Who is the CEO of EKF Diagnostics? | EKF Diagnostics' CEO is Gavin Joseph Jones. |
| Is EKF Diagnostics publicly listed? | Yes, EKF Diagnostics is a public company listed on London Stock Exchange. |
| What is the stock symbol of EKF Diagnostics? | EKF Diagnostics trades under EKF ticker. |
| When did EKF Diagnostics go public? | EKF Diagnostics went public in 2002. |
| Who are competitors of EKF Diagnostics? | EKF Diagnostics main competitors are Nyxoah, Guerbet, AVITA Medical, Biodesix. |
| What is the current market cap of EKF Diagnostics? | EKF Diagnostics' current market cap is $143M. |
| What is the current revenue of EKF Diagnostics? | EKF Diagnostics' last 12 months revenue is $70M. |
| What is the current revenue growth of EKF Diagnostics? | EKF Diagnostics revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of EKF Diagnostics? | Current revenue multiple of EKF Diagnostics is 1.8x. |
| Is EKF Diagnostics profitable? | Yes, EKF Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of EKF Diagnostics? | EKF Diagnostics' last 12 months EBITDA is $17M. |
| What is EKF Diagnostics' EBITDA margin? | EKF Diagnostics' last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of EKF Diagnostics? | Current EBITDA multiple of EKF Diagnostics is 7.4x. |
| What is the current FCF of EKF Diagnostics? | EKF Diagnostics' last 12 months FCF is $8M. |
| What is EKF Diagnostics' FCF margin? | EKF Diagnostics' last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of EKF Diagnostics? | Current FCF multiple of EKF Diagnostics is 15.0x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.